Clinical efficacy evaluation and prevention of adverse reactions in a randomized trial of a combination of three drugs in the treatment of cancerous pudendal neuralgia
| Autor: | Junjie Hou, Yifan Lin, Yanqiu Fang, Xiaonan Li, Xiao-Nan Li, Ying Yang, Ning Liu, Xianzhuo Jiang, Yingying Yu, Ying Zhou, Xuguang Mi, Zhiqiang Ni, Xiaodan Lu, Ning-Yi Jin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pregabalin
law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans Dysuria Pudendal Neuralgia Advanced and Specialized Nursing Urinary retention business.industry Pudendal neuralgia medicine.disease Clinical trial Treatment Outcome Anesthesiology and Pain Medicine Pharmaceutical Preparations 030220 oncology & carcinogenesis Anesthesia Quality of Life Celecoxib 030211 gastroenterology & hepatology medicine.symptom business Tamsulosin hydrochloride medicine.drug |
| Zdroj: | Annals of Palliative Medicine. 10:5754-5762 |
| ISSN: | 2224-5839 2224-5820 |
| DOI: | 10.21037/apm-21-590 |
| Popis: | BACKGROUND To explore the clinical efficacy, safety, and prevention of major adverse reactions of the non-steroidal anti-inflammatory drug celecoxib combined with OxyContin and Pregabalin in the treatment of cancerous pudendal neuralgia. METHODS A total of 51 patients presenting with pelvic malignancies with cancerous pudendal neuralgia were selected, and random number table method was used to allocate them to either the experimental group (n=27) or control group (n=24). The control group was treated with OxyContin combined with Pregabalin, and the experimental group was treated with Celecoxib on the basis of the control group. RESULTS At 24 hours after treatment, the clinical effective rate of the experimental group was 92.6%, which was significantly higher than the 66.7% of the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|